LeonaBio (ATHA) CEO converts 22,254 RSUs and sells shares for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
LeonaBio, Inc. President and CEO Mark James Litton reported several equity transactions involving company stock. On March 3, 2026, 22,254 restricted stock units were exercised at $0.00 per share, converting into the same number of common shares and bringing his direct common stock holdings to 63,082 shares.
On March 4, 2026, 5,156 common shares were sold at a weighted-average price of $5.37 per share to cover tax withholding obligations triggered by the RSU vesting under the company’s mandatory “sell to cover” policies; no additional shares were sold. After this tax-related sale, he directly owned 57,926 common shares. Separate irrevocable trusts established for his children each held 656 common shares as indirect ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 5,156 shares ($27,688)
Net Sell
6 txns
Insider
Litton Mark James
Role
PRESIDENT and CEO
Sold
5,156 shs ($28K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 5,156 | $5.37 | $28K |
| Exercise | Restricted Stock Units | 22,254 | $0.00 | -- |
| Exercise | Common Stock | 22,254 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 57,926 shares (Direct);
Restricted Stock Units — 0 shares (Direct);
Common Stock — 656 shares (Indirect, By Irrevocable Trust of OSL)
Footnotes (1)
- Represents shares of common stock sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units ("RSU") pursuant to mandatory "sell to cover" policies maintained by the Issuer and provisions contained in the reporting person's applicable RSU agreement, and does not represent a discretionary sale by the reporting person. No additional shares of common stock were sold by the reporting person. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Reflects Common Stock held by Irrevocable Trust of OSL held for the benefit of Dr. Litton's children. Reflects Common Stock held by Irrevocable Trust of SWL held for the benefit of Dr. Litton's children. Reflects Common Stock held by Irrevocable Trust of WGL held for the benefit of Dr. Litton's children. Each RSU represents a contingent right to receive one (1) share of Issuer's common stock. On March 3, 2025, the reporting person was granted 22,254 RSUs (as adjusted for the 10-for-1 reverse stock split completed on September 17, 2025). 100% of the RSUs vested on the one (1) year anniversary of the grant date.
FAQ
What insider stock transactions did LeonaBio (ATHA) report for its CEO?
LeonaBio’s President and CEO Mark James Litton exercised 22,254 restricted stock units into common shares, then sold 5,156 shares. The sale was solely to cover tax withholding obligations from the RSU vesting under mandatory company policies, leaving him with 57,926 directly held shares.
How many LeonaBio (ATHA) RSUs vested and converted for the CEO?
22,254 LeonaBio restricted stock units vested and converted into the same number of common shares for CEO Mark James Litton. These RSUs were originally granted on March 3, 2025, and fully vested on the one-year anniversary of the grant, following the company’s equity award terms.